Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug pipeline: 2Q18

Through the first half of 2018, US Food and Drug Administration (FDA) approvals lagged relative to last year, but the agency's calendar looks busy ahead, with decisions for several acute myelogenous leukemia drugs in particular. Amgen's monoclonal antibody (mAb) Aimovig (erenumab) was approved for migraine; and there was a rash of approvals for both rare disorders (X-linked hyperphosphatemia; immune thrombocytopenic purpura; familial amyloidotic cardiomyopathy and phenylketonuria) and infectious diseases (urinary/reproductive tract infections and river blindness). Europe pulled conditional approval of Sarepta's exon-skipping drug, Exondys 51, for Duchenne muscular dystrophy; the FDA continues to monitor closely experimental gene-edited cell therapies being taken into the clinic.

Historic US regulatory approvals by lead indicationboxed-text

Notable regulatory setbacks (2Q18)boxed-text

Notable clinical trial results (2Q18)boxed-text

Notable regulatory approvals (2Q18)boxed-text

Notable upcoming catalysts (4Q18)boxed-text

Author information



Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L. Drug pipeline: 2Q18. Nat Biotechnol 36, 677 (2018).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing